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ABSTRACT 
Title: MYOSTATIN RELATED GENE 
ASSOCIATIONS WITH MUSCLE MASS AND 
STRENGTH IN HUMANS 
 
     Sean Walsh, Ph.D., 2006 
Directed by:    Assistant Professor Stephen M. Roth, 
     Department of Kinesiology 
 
INTRODUCTION: The gradual decline in muscle mass with age is known as sarcopenia, 
and has been associated with an increased risk of falls, hip fractures, and functional 
decline.  However, there is large inter-individual variability in this decline, even among 
people of a similar age and sex.  Heritability studies have shown that genetic factors can 
account for up to 90% of this variation in muscle mass and ~65% in muscle strength.  
Myostatin is a negative regulator of skeletal muscle and plays a key role in muscle 
development and the maintenance of muscle mass. However, DNA sequence variation 
within this gene has not been consistently associated with skeletal muscle mass nor 
muscle strength in humans.  PURPOSE: The purpose of this dissertation was to examine 
genetic variation in follistatin and Activin RIIB (ACVR2B), two myostatin related genes, 
to explore associations with skeletal muscle related phenotypes.  METHODS: Three 
hundred fifteen Caucasian males and 278 Caucasian females aged 19-90 years from the 
Baltimore Longitudinal Study of Aging were genotyped to determine respective 
haplotype groupings.  Whole-body soft tissue composition was measured by dual-energy 
X-ray absorptiometry.  Peak torque (strength) was measured using an isokinetic 
dynamometer.  RESULTS: Women heterozygous for ACVR2B haplotype groups 1 and 2 
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exhibited significantly less concentric quadriceps muscle strength than women 
homozygous for haplotype group 2 (108.7 ± 2.2 vs 118.6 ± 4.1 N·m, .52rad/sec, 
respectively, p <0.05).  No significant association was observed in men.  However, men 
homozygous for follistatin haplotype group 1 exhibited significantly greater total leg 
FFM than men heterozygous for follistatin haplotype groups 1 and 3 (17.8 ± 0.2 vs 16.7 ± 
0.4 kg, respectively, p <0.05) and significantly greater total leg FFM than non-carriers of 
follistatin haplotype group 1 (17.8 ± 0.2 vs 16.5 ± 0.5 kg, respectively, p <0.05).  
Moreover, male carriers of follistatin haplotype group 3 exhibited significantly less total 
leg FFM than non-carriers (16.6 ± 0.3 vs 17.5 ± 0.2 kg, respectively, p <0.05).  No 
significant associations between these groups were observed in women.  
CONCLUSIONS: The data indicate that the ACVR2B and follistatin loci may contribute 
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INTRODUCTION 
Skeletal muscle mass gradually declines starting at about age 45 years (61) and it 
is estimated that after the fifth decade 6% of muscle mass is lost per decade until the 
eighth decade of life in men (80).  This loss of muscle mass that occurs with healthy 
aging is commonly known as sarcopenia, a Greek term coined by Rosenberg referring to 
the “poverty of flesh” (106) denoting this tissue loss with age.  $18.5 billion dollars was 
the estimated direct healthcare cost attributable to sarcopenia in 2000 and it is currently 
estimated that ~45% of the older population ( > 60 yrs of age) is sarcopenic (61) with 
sarcopenic women having 3.6 times higher rates of disability and men 4.1 times higher 
rates of disability than non-sarcopenic individuals (8).   Furthermore, the loss of muscle 
strength is an independent predictor of mortality in the elderly (88; 101).  The negative 
economic impact of sarcopenic related disability at the societal level is clear, while the 
cost of the reduction in quality of life for these individuals can’t be easily calculated. 
Despite its relatively short history, myostatin has quickly become an established 
target of study for skeletal muscle researchers interested in identifying mechanisms of 
muscle development and therapies for muscle-related disorders.  First reported in 1997 by 
McPherron et al. (85), myostatin (growth and differentiation factor-8) was identified in 
mice as a transforming growth factor-β (TGF-β) family member that acts as a negative 
regulator of skeletal muscle growth.  Soon after the initial report of myostatin’s 
discovery, several groups identified mutations in the myostatin gene in naturally-bred 
“double-muscled” cattle breeds (41; 86), providing additional evidence for a critical role 
for myostatin in muscle development, and thus establishing myostatin as the key target it 
has become for muscle researchers. 
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Identifying how myostatin influences skeletal muscle and what processes regulate 
myostatin expression and activity has dominated the myostatin literature in the past few 
years.  Following up their initial discovery, Lee and McPherron (74), established putative 
myostatin receptors (activin-type II receptors A and B; ACVR2A and B) and negative 
regulators (the myostatin propeptide and follistatin), and formalized a basic model of 
myostatin regulation.  With the identification of ACVR2B as a primary myostatin 
receptor and the myostatin propeptide (124; 139) and follistatin as negative regulators of 
myostatin activity, Lee and McPherron (74) put forth the following model of myostatin 
regulation in 2001: the myostatin C-terminal dimer remains in a latent complex with the 
inhibitory propeptide. This latent complex can be further negatively regulated by binding 
with follistatin, and upon release of the negative regulators, myostatin is free to signal 
through its receptors, primarily ACVR2B.  Lee and McPherron (74) demonstrated that 
myostatin binding to ACVR2B receptors was specific and saturable, and transgenic mice 
with increased muscle expression of a dominant negative form of ACVR2B had 
increased muscle weights, with individual muscles weighing up to 125% more than those 
of control nontransgenic animals.   
Several studies have shown that follistatin can function as a potent myostatin 
antagonist and plays an important role in vivo.  First, follistatin is capable of blocking 
myostatin activity in both receptor binding and reporter gene assays (74; 142).  Secondly, 
genetic studies in mice have shown that overexpression of follistatin in muscle can cause 
dramatic increases in muscle growth.  Lee and McPherron (74) generated transgenic mice 
in which the myosin light chain promoter/enhancer was used to drive the expression of 
follistatin and dramatic effects on skeletal muscle were seen.  In one animal muscle 
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weights were increased by 194-327% relative to control animals; thus it appears, 
follistatin appears to be a potent myostatin antagonist (74). 
Despite myostatin’s remarkable influence on skeletal muscle and the well-
established effect of myostatin gene mutations in double-muscled cattle breeds, studies of 
myostatin genetic variation in humans have shown little association with muscle 
phenotypes.  Ferrell and coworkers (33) identified several common polymorphisms in the 
human myostatin gene, with six nucleotide changes observed, of which five are predicted 
to lead to amino acid sequence changes, but in follow-up work by that group and others 
only minor associations have been observed for the most common of these 
polymorphisms with muscle mass or strength (58; 118).   Scheulke and colleagues (116) 
reported a novel loss-of-function mutation in the myostatin gene of a young child who 
when born appeared extraordinarily muscular, with protruding muscles in his thighs and 
upper arms.  However, the mutation is not common and is considered rare. The mutation 
was absent in 200 alleles from control subjects with a similar ethnic background.  Recent 
work has focused on genetic variation in myostatin pathway genes (55; 56),  specifically 
genes involved in the signaling cascade once myostatin signaling has been initiated. 
However, myostatin pathway genes upstream of this signaling cascade have yet to be 
examined. 
Therefore, the purpose of this study was to examine genetic variation in follistatin 
and ACVR2B to determine associations with skeletal muscle mass and skeletal muscle 
strength.   
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HYPOTHESES 
Hypothesis 1:  Polymorphic genetic variation in a primary myostatin receptor, 
ACVR2B, will be associated with significantly different levels of muscle mass 
and strength. 
 
Hypothesis 2:  Polymorphic genetic variation in follistatin will be associated with 




















The subjects included in this study were Caucasian and came from the Baltimore 
Longitudinal Study of Aging (BLSA), an ongoing NIA-funded investigation of normal 
aging.  All volunteer subjects enrolled in this study  receive a complete physical 
examination, a bone scan, a joint pain assessment questionnaire, a physical-activity 
questionnaire, and a functional assessment, among other tests; those with clinical 
cardiovascular and musculoskeletal disease are excluded, as are subjects with active neck 
and back pain, frequent and severe joint pain, prior joint surgery, prior bone scan below 
normal for their age, any recent (6 mo) major surgery, or other condition that might be 
aggravated by testing. All subjects are asked questions on a physical-activity 
questionnaire concerning their involvement in weight training exercise. The average 
number of minutes per week is recorded, analyzed, and compared among the various age 
groups.  Only a very small percentage of subjects (<1%) participate in any type of regular 
resistive exercise, and there is no significant difference in participation by age or gender 
(77).  Before the study, all subjects receive a complete explanation of the purpose and 
procedures of the investigation and give their written informed consent. 
Body Composition 
Data collected for body composition variables were obtained using methods 
previously approved by the BLSA (77).  Body mass and height were measured to the 
nearest 0.1 kg and 0.5 cm, respectively, using a Detecto medical beam scale.  Total body 
fat and soft tissue fat free mass (FFM) and total leg fat and FFM (both legs combined) 
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were assessed by dual-energy X-ray absorptiometry (DEXA) (model DPX-L Lunar 
Radiation, Madison, WI) using previously described methods (77).  Soft tissue  FFM was 
used as a valid indicator of muscle mass based on previous work (39; 136).  
Measurement of Muscle Strength 
Data collected for muscle strength variables were obtained using methods 
previously approved by the BLSA (77).  Peak torque (strength) was measured using the 
Kinetic Communicator isokinetic dynamometer (Kin-Com model 125E, Chattanooga 
Group, Chattanooga, TN). Concentric (Con) peak torque was measured at angular 
velocities of 0.52 rad/s (30 deg/sec) and 3.14 rad/s (180 deg/sec) for the dominant knee 
extensors.  All subjects performed a 5-min warm-up on a stationary cycle ergometer, 
followed by mild stretching of the hamstring and quadriceps muscle groups.  Three 
graded submaximal practice repetitions were performed prior to each test. For each test, 
subjects performed three maximal efforts, separated by 30-s rest intervals. Each test is 
separated by a 2-min rest period. The best of the three maximal efforts was used as peak 
torque.  Peak torque was assessed by using the Kin-Com computer software (version 3.2). 
Reliability of strength testing when using the Kin-com dynamometer has been reported 
elsewhere (50). However, Lindle et al. (77) performed a test-retest reliability study using 
10 older men to determine reliability of the specific test machine and protocol used by the 
BLSA.  Subjects were tested twice, separated by a 1-wk interval.  For concentric torques 
at both test velocities in the knee extensor muscle groups, intra-class correlation 
coefficients ranged between 0.96 and 0.99.  Coefficients of variation ranged between 
1.5 and 7.5%, with a mean coefficient of variation value for all tests of 5%.  Detailed 
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procedures regarding subject positioning and stabilization, gravity correction, and Kin-
Com calibration are described elsewhere (77; 80).  
Haplotype Block Determination 
 A graphical genome browser maintained by the International HapMap Project 
website (http://www.hapmap.org) was used to navigate to the particular regions 
surrounding the candidate genes of interest and retrieve HapMap genotype data for all 
genotyped markers in the selected regions in a format accepted by Haploview, a software 
program designed to provide a number of tools for haplotype analysis (6).  Haploview 
calculated pairwise measures of linkage disequilibrium (LD) among the polymorphisms 
in each region and created haplotype blocks based on the definition of haplotype blocks 
provided by Gabriel and colleagues, one of several commonly used block definitions 
used to partition the region of interest into segments of strong LD (6).  Block structures 
and specific polymorphisms for each gene are shown in the results section. 
Haplotype Grouping 
One issue inherent in haplotype association studies is haplotype complexity.  
Although haplotypes may be more informative than single markers, the power of 
haplotype analysis is reduced by the potentially large number of haplotypes that are 
present in large haplotype blocks.  A statistical approach known as the sliding window 
has been developed to address this issue (9; 20; 126; 141).  The sliding window helps to 
focus on the candidate region of interest and assess evidence for association within each 
window, helping to reduce the dimensionality of haplotype analysis (141).  Therefore, 
given the size and complexity of the block containing the follistatin gene, the four single 
nucleotide polymorphisms (SNPs) closest to the follistatin gene that fell within the 
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greater haplotype block structure were used as the window for analysis regarding this 
haplotype in order to create three haplotype groups rather than five groups.  The rationale 
for inclusion of these four SNPs is that all four of these SNPs fall within the follistatin 
gene, therefore any true causal variants within the follistatin gene would be linked to one 
of the three haplotype groups analyzed.   
Genotyping 
All subjects participating in the present study consented to and provided DNA for 
genetic analysis of muscle-related phenotypes.  Standard procedures were used to obtain 
a 10 ml blood sample from consented subjects, and genomic DNA was prepared from the 
EDTA-anticoagulated whole blood samples by standard salting-out procedures (Puregene 
DNA Extraction, Gentra Systems Inc.).  Genotyping of SNPs was performed using the 5' 
nuclease allelic discrimination or TaqMan assay (79) for high-throughput genotyping. 
 Each 12.5 µL polymerase chain reaction (PCR) contained 1.5 µL (10-20 ng) of 
genomic DNA, 0.625 µL of 20X diluted SNP mix (SNP rs #’s are shown in the results 
section), 4.125 µL DNAse free dH20, and 6.25 5 µL of 2X TaqMan Universal PCR 
master mix (Perkin-Elmer, Applied Biosystems Division), which is a solution containing 
buffer, Uracil-N-glycosylase, deoxyribonucleotides, uridine, passive reference dye 
(ROX), and TaqGold DNA polymerase. The PCR cycling protocol consisted of the 
following: 50º  for 2 minutes, 95 º for 10 minutes, 70 cycles of 92 º for 15 seconds and 60 
º for 1 minute.  Fluorescence in each well was measured using an ABI 7300 Real Time 
PCR System machine (Perkin Elmer, Applied Biosystems Division).  Analysis of raw 
data to determine genotypes was performed by the ABI 7300 Sequence Detection System 
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software.  For quality control purposes, twelve samples were directly sequenced for each 
assay and used in each 96 well plate as sequencing controls.    
Statistical Analyses 
Statistical analysis relied on analysis of co-variance (ANCOVA) to compare 
means among haplotype groups for all outcome variables controlling for possible 
confounding factors by adding covariates such as age, height, and weight when 
significant.  Given the complexity of the follistatin haplotype structure, specific 
haplotype groups were collapsed to improve statistical power (Appendix C). Analyses 
were performed within each sex group.  Data presented are least squares means ± 
standard error (SE), except where noted.  Analysis of variance (ANOVA) models were 
used to test for differences in physical characteristics among ACVR2B and follistatin 
haplotype groups.  Physical characteristic data are presented as means ± SE.  Statistical 
significance for the ANCOVA and ANOVA models was accepted at p < 0.05.  For all 
non-significant results, the omnibus p-value is shown in the tables; for all significant 
results, the specific contrast p-values are reported.  
 All analyses shown were performed in Caucasians only.  Although the BLSA 
cohort is of mixed race (though predominantly Caucasian), differences in allele 
frequencies for each of the three SNPs in the present study between Caucasians and 
African Americans prevented combining race groups for statistical analysis.  Although 
underpowered due to small sample size, exploratory analyses performed in African 
Americans only did not reveal any significant associations (data not shown). 
 
  




ACVR2B Receptor Haplotype  
 
HapMap database research into the haplotype structure of the genome sequence 
surrounding the myostatin receptor gene, ACVR2B, revealed the following haplotype (Hap) 
block and frequencies: 
Table 1: ACVR2B Haplotype Structure. 
 Snp1 Snp3 Snp5 Snp8 Snp10 Snp11 Snp14 Snp15 Snp16 Freq 
Hap 1 A T T T A A A T T 0.615 
Hap 2 C C C C G G C C G 0.273 
Hap 3 C C C C G A A T G 0.05 
Hap 4 A T T T A G A T T 0.034 
Hap 5 C C C C A G C C G 0.01 
 
Genotyping SNP 8 (rs: #2268757), located in intron 1 of the ACVR2B gene, 
captured the majority of the information of this haplotype block and created two related 
Haplotype Groups.  Hap1 (.615) along with Hap 4 (.034) were considered one group 
(Haplotype Group 1) due to their high degree of similarity, sharing eight of nine alleles, 
and Hap 2 (.273), Hap 3 (.05), and Hap 5 (.01) were considered a second haplotype group 
(Haplotype Group 2), sharing a minimum of five of nine alleles to a maximum of eight of 
nine alleles.  
 In men, haplotype group frequencies were 25.1 % for homozygous haplotype 
group 1, 58.4 % for heterozygous haplotype groups 1 & 2, and 16.5 % for homozygous 
haplotype group 2, while in women, haplotype group frequencies were 23.7 % for 
homozygous haplotype group 1, 58.1% for heterozygous haplotype groups 1 & 2, and 
18.2 % for homozygous haplotype group 2.  Subject characteristics are shown by 
ACVR2B haplotype group in Table 2.  No significant differences existed by ACVR2B 
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haplotype group for any physical characteristic, however, women heterozygous for 
haplotype groups 1 and 2 tended to be younger in comparison to the other haplotype 
groupings. 





Haplotype Group 1 
Heterozygous 
Haplotype 
Groups 1 & 2 
 
Homozygous 
Haplotype Group 2 
P-value 
  MEN   
N 78 181 51  
Age (y) 64.6 ± 1.9 62.1 ± 1.2 59.4 ± 2.4 0.228 
Height (cm) 176.6 ± 0.8 176.2 ± 0.6 176.1 ± 1.0 0.92 
Weight (kg) 86.2 ± 1.5 83.6 ± 1.0 83.9 ± 1.8 0.34 
  WOMEN   
N 70 172 54   
Age (y) 59.4 ± 1.9 a 55.0 ± 1.2 b 59.4 ± 2.1 c a vs b 0.051 
b vs c 0.073 
Height (cm) 163.3 ± 0.8 163.3 ± 0.5 163.4 ± 0.9 0.99 
Weight (kg) 68.4 ± 1.5 67.5 ± .9 65.7 ± 1.7 0.48 
Data are means ± SE.   
As shown in Table 3, women heterozygous for haplotype groups 1 and 2 
exhibited significantly less concentric quadriceps muscle strength than women 
homozygous for haplotype group 2 (108.7 ± 2.2 vs 118.6 ± 4.1 N·m, 30º/sec, 
respectively, p= 0.036).  In a combined analysis of carriers of haplotype group 1 versus 
homozygous haplotype group 2 the same association was observed (109.2 ± 1.9 vs 118.6 
± 4.1 N·m, 30º/sec, respectively, p= 0.039).  No significant strength differences among 
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Table 3: Concentric knee extensor peak torque values by ACVR2B haplotype in 














    MEN       
N  80  184   49    
Concentric 
(N·m, 30º/sec) 
175.7 ± 4.5  167.7 ± 3.0 172.8 ± 5.8 0.307  
Concentric 
(N·m, 180º/sec 
117.6 ± 2.9  114.2 ± 2.0 118.0 ± 3.7 0.495  
  WOMEN 
 
  
N 61 158 48   
Concentric 
(N·m, 30º/sec) 
110.5 ± 3.6  108.7 ± 2.2 a 118.6 ± 4.1 b a vs b 0.036 
   
Concentric 
(N·m, 180º/sec 
72.8 ± 2.4  70.4 ± 1.5 75.4 ± 2.7 0.250 
Data are least squares means ± SE.  Age and height were included in the model as significant 
covariates. 
 
No significant differences were observed in total body FFM or total leg FFM in 
either men or women by ACVR2B haplotype group, however there was a tendency for 
ACVR2B haplotype to be associated with these phenotypes in both men and women.  As 
shown in Table 4, men heterozygous for haplotype groups 1 and 2 tended to have slightly 
lower total body FFM (p = 0.066) and lower total leg FFM (p = 0.07) than men 
homozygous for haplotype group 1, while women homozygous for haplotype group 2 
tended to have slightly lower total body FFM than women homozygous for haplotype 
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    MEN  
 
    
 N  78  181  51   
Total Body FFM (kg) 57.8 ± 0.5 a 56.5 ± 0.3 b 57.8.0 ± 0.7  a vs b 0.066 
Total Leg FFM (kg) 17.7 ± 0.3 a 16.9 ± 0.2 b 17.5 ± 0.4 a vs b 0.07 
  WOMEN   
N  70  172  54   
Total Body FFM (kg) 40.1 ± 0.4 a 39.4 ± 0.2  39.1 ± 0.5 b a vs b 0.10 
Total Leg FFM (kg) 11.3 ± 0.2  11.3 ± 0.1 11.2 ± 0.3 0.891 





HapMap database research into the haplotype structure of the genome sequence 
surrounding the follistatin gene revealed the following haplotype block and frequencies: 
Table 5: Follistatin Haplotype Structure. 
  Snp1 Snp2 Snp3 Snp4 Snp5 Snp6 Snp7 Freq 
Hap 1 A C C C T A T 0.367
Hap 2 A C C T C A C 0.217
Hap 3 A A T C T A C 0.20 
Hap 4 G C C C T G T 0.133
Hap 5 G C C C T A T 0.042
  
SNPs 2, 3, 4 & 5 comprise all the SNPs within the follistatin gene within this 
block and are all intronic.  SNP 2 (rs: # 3797297) is located 7,677 base pairs downstream 
of SNP 1 (rs: # 10080213) while SNP 4 (rs: #12152850) resides 233 base pairs upstream 
of SNP 5 (rs: # 12153205).  By genotyping SNP 2 (rs: # 3797297) and SNP 4 (rs: # 
12152850) the majority of the information of this haplotype structure could be gained.  
Genotyping SNP 2 (rs: # 3797297) separated Hap 3 (Haplotype Group 3) from the rest of 
the haplotypes and by genotyping SNP 4 (rs: #12152850) Hap 2 (Haplotype Group 2) 
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was separated from the remaining haplotypes creating a final group of Hap 1, Hap 4, and 
Hap 5 (Haplotype Group 1) that share a minimum of four of six alleles.  In some 
analyses, different combinations of these three haplotype groups were collapsed to 
improve statistical power. 
In men, haplotype group frequencies were 40.6 % for homozygous haplotype 
group 1, 1.3 % for homozygous haplotype group 2, 3.8 % for homozygous haplotype 
group 3, 21.3 % for heterozygous haplotype groups 1 & 2, 26.3 % for heterozygous 
haplotype groups 1 & 3, and 6.7 % for heterozygous haplotype groups 2 & 3, while in 
women, haplotype group frequencies were 38.8 % for homozygous haplotype group 1, 
3.6 % for homozygous haplotype group 2, 6.1 % for homozygous haplotype group 3, 
19.1 % for heterozygous haplotype groups 1 & 2, 23.4 % for heterozygous haplotype 
groups 1 & 3, and 9.0 % for heterozygous haplotype groups 2 & 3.  Subject 
characteristics are shown by follistatin haplotype group in Table 6.  Men homozygous for 
haplotype group 1 were significantly younger than men heterozygous for haplotype 
groups 1 & 2 (p=0.015) and men heterozygous for haplotype groups 1 & 3 (p= 0.004).  
Women homozygous for haplotype group 1 weighed significantly less than women 
heterozygous for haplotype groups 1 & 2 (p=0.005), while non-carriers of haplotype 
group 1 also weighed significantly less than women heterozygous for haplotype groups 1 
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Table 6:  Subject characteristics for Follistatin haplotype group 1 homozygous 
carriers, haplotype group 1 heterozygous carriers, and non-carriers of haplotype 




















N 128 67 83 37  
Age (y) 59.4 ± 1.5 a 65.4 ± 2.0 b 66.1 ± 1.8 c 58.9 ± 2.7 d a vs b 0.015 
a vs c 0.004 
b vs d 0.052 
c vs d 0.027 
Height (cm) 176.9 ± 0.7 175.3 ± 0.9 176.1 ± 0.8 175.9 ± 1.2 0.533 
Weight (kg) 85.4 ± 1.1 82.8 ± 1.6 83.1 ± 1.4 85.6 ± 2.1 0.388 
WOMEN 
N 108 53 65 52  
Age (y) 58.8 ± 1.5 55.7 ± 2.2  55.8 ± 2.0 57.3 ± 2.3 0.583 
Height (cm) 163.2 ± 0.7 164.9 ± 0.9 163.1 ± 0.8 162.3 ± 0.9 0.258 
Weight (kg) 65.4 ± 1.2 a  71.3 ± 1.7 b 68.9 ± 1.5 c 66.4 ± 1.7 d a vs b 0.005 
a vs c 0.066 
b vs d 0.045 
Data are means ± SE.   
 As shown in Table 7, men homozygous for haplotype group 1 exhibited 
significantly more total leg FFM than men heterozygous for haplotype groups 1 and 3 
(17.8 ± 0.2 vs 16.7 ± 0.4 kg, respectively, p=0.007) and exhibited significantly more total 
leg FFM than non-carriers of haplotype group 1 (17.8 ± 0.2 vs 16.5 ± 0.5 kg, 
respectively, p=0.023). Also, when men homozygous for haplotype group 1 were 
compared to men heterozygous for haplotype groups 1 and 3 there was tendency for 
higher levels of total body FFM (57.4 ± 0.4 vs 56.1 ± 0.5 kg, respectively, p=0.061). No 
significant differences were observed for muscle strength phenotypes in men (Appendix 
E-Table A).  No significant associations were observed for FFM or muscle strength 
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Table 7: Soft tissue FFM variables for Follistatin haplotype group 1 homozygous 
carriers, haplotype group 1 heterozygous carriers, and non-carriers of haplotype 










Groups 1 & 2 
Heterozygous 
Haplotype 







        (N) 
57.4 ± 0.4 a  
 
(128) 
56.8 ± 0.6 
 
(67) 
56.1 ± 0.5 b  
 
(83) 
57.9 ± 0.8  
 
(37) 
a vs b 0.061 
  
Total Leg FFM 
(kg)  
(N) 
17.8 ± 0.2 a 
 
(116) 
17.1 ± 0.4 
 
(62) 
16.7 ± 0.3 b 
 
(72) 
16.5 ± 0.5 c 
 
(36) 
a vs b 0.007 
 









Groups 1 & 2 
Heterozygous 
Haplotype 
Groups 1 & 3 
Non-Carriers 
of Haplotype  




        (N) 
39.5 ± 0.4  
 
(108) 
39.7 ± 0.4  
 
(53) 
39.5 ± 0.3  
 
(65) 





Total Leg FFM 
(kg)  
(N) 
11.1 ± 0.2   
 
(99) 
11.4 ± 0.3  
 
(49) 
11.6 ± 0.3  
 
(61) 






Data are least square means ± SE.  Age and height were included in the model as significant 
covariates.   Weight was added as an additional significant covariate for the female analysis. 
 
Due to statistical power limitations a sub-analysis was performed by collapsing all 
carriers of haplotype group 2 into one group and all non-carriers of haplotype group 2 
into a second group.  No significant differences were observed for any muscle mass or 
muscle strength phenotypes in the sub-analysis of haplotype group 2, data not shown 
(Appendix E-Tables C & D).  Similarly, a sub-analysis was performed for haplotype 
group 3 by collapsing all carriers of haplotype group 3 into one group and all non-carriers 
of haplotype group 3 into a second group.  Subject characteristics are shown in Table 8.  
As shown in Table 9, male carriers of haplotype group 3 exhibited significantly less total 
FFM than non-carriers of haplotype group 3 (16.6 ± 0.3 vs 17.5 ± 0.2 kg, respectively, p= 
0.012) and displayed a tendency to have lower total body FFM as well (56.3 ± 0.5 vs 57.4 
± 0.3 kg, respectively, p= 0.055).  No significant differences were observed in either men 
17   
 
or women for muscle strength for the haplotype 3 sub-analysis (Appendix E-Table E).   
 
Table 8:  Subject characteristics for Follistatin haplotype group 3 carriers and non-




Haplotype Group 3 
Non-Carriers of 




N 111 204  
Age (y) 64.3 ± 1.6 61.3 ± 1.1 0.123 
Height (cm) 176.3 ± 0.7 176.2 ± 0.5 0.877 
Weight (kg) 83.8 ± 1.2 84.5 ± 0.9 0.636 
WOMEN 
N 107 171  
Age (y) 56.2 ± 1.5 57.9 ± 1.2  0.387 
Height (cm) 162.7 ± 0.7 163.7 ± 0.5 0.236 
Weight (kg) 67.8 ± 1.2 67.3 ± 0.9 0.718 
Data are means ± SE. 
   
Table 9:  Soft tissue FFM variables by carriers and non-carriers of haplotype group 











Total Body FFM (kg) 
(N) 
56.3 ± 0.5  
(111) 
57.4 ± 0.3  
(204) 
 0.055 
Total Leg FFM (kg) 
(N) 
16.6 ± 0.3  
(93) 




Total Body FFM (kg) 
(N) 
39.7 ± 0.3 
(107)  
39.3 ± 0.3  
(171) 
0.458  
Total Leg FFM (kg) 
(N) 
11.5 ± 0.2  
(97) 
11.2 ± 0.2 
(158) 
 0.276 













The principal findings of the present study indicate that the ACVR2B and 
follistatin loci may contribute to the inter-individual variation in muscle mass and 
strength phenotypes.  The present study is one of the first to explore haplotype structure 
of candidate genes and their associations with skeletal muscle phenotypes.  The use of 
haplotype structure has previously served as a tool for human genetic research with the 
initial step of first finding an association to a haplotype, and then subsequently 
identifying the causal mutation(s) that it carries (123). This tool has played a key 
beginning role in helping identify causal genes for mendelian diseases such as diastrophic 
dysplasia (48) and cystic fibrosis (64), and recently for complex disorders such as age-
related macular degeneration (29; 45; 65; 123).  Previous work has shown that there is 
inter-individual variability in the loss of muscle strength with age (77) indicating a 
potential role for genetic variability in the risk for sarcopenia (107).   Given the 
complexity of skeletal muscle mass and strength, the present results regarding the 
haplotype structure of ACVR2B and follistatin will need to be verified in other 
populations with subsequent studies aimed at identifying causal mutations.   
To our knowledge, the present study is the first to explore associations between 
the haplotype structures of the follistatin and ACVR2B genes with skeletal muscle mass 
and strength phenotypes.  Men heterozygous for follistatin haplotype groups 1 & 3 
exhibited significantly less total leg FFM than men homozygous for follistatin haplotype 
group 1 and there was a tendency for the same observation in regards to total body FFM.  
Similarly, male carriers of follistatin haplotype group 3 also showed significantly less 
total leg FFM than non-carriers.  It appears that the influence of follistatin haplotype 
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group 3 has a negative impact on skeletal muscle mass in men.  Sowers and colleagues 
have shown that the loss of 2.5 kg of total lean mass over a 3 year period resulted in 
lower levels of physical functioning (119).  When examining the difference in skeletal 
muscle mass with follistatin haplotype structure, in specific total leg FFM differences, 
follistatin haplotype structure was associated with a 1.3 kg difference in FFM.  We feel 
that leg muscle mass could be a stronger indicator of physical functioning than total lean 
mass.  Lower extremity function has been shown to accurately predict disability across 
diverse populations (44).  Work by Rolland et al. (105) has shown that older individuals 
with lower calf circumferences have greater disability and lower physical function 
leading the authors to suggest “that topography of muscle loss is more associated than 
global muscle mass loss with physical function and disability”.  Although we don’t have 
physical function measures as in the Sowers et al. study, given the importance of muscle 
mass to physical functioning, a difference of 1.3 kg of total leg FFM is likely 
physiologically significant for physical function.   
Women carriers of ACVR2B haplotype group 1 exhibited significantly less 
skeletal muscle strength than women homozygous for ACVR2B haplotype group 2 when 
measured as isokinetic peak torque at 30º /sec.  The difference of ~10 N·m between 
groups is important when considering the age of these subjects.  In a longitudinal study 
by Hughes et al. (53) involving older female subjects (60.4 ± 7.4 yrs) the women 
experienced a 12% decrease in knee extensor strength (-11 N·m) over an ~ 10 year 
follow-up period, measured as isokinetic peak torque at  60º/sec.  The difference in 
muscle strength associated with ACVR2B haplotype is similar to losses of skeletal 
muscle strength that occurred over a decade in women in the study by Hughes et al.  
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Given the well documented impact that the loss of skeletal muscle strength has on the 
slowing of gait speed, increased risk in falls and hip fractures (4; 15; 100), and as an 
independent predictor of mortality in the elderly (88; 101),  the difference in skeletal 
muscle strength observed in this present study may have important implications.  These 
findings, if verified, may allow for the identification of women who are genetically 
susceptible to low levels of muscle strength.   
The present study is not the first to examine genes within the myostatin pathway 
for an influence on skeletal muscle phenotypes.  Despite myostatin’s remarkable 
influence on skeletal muscle in animal models, studies of myostatin genetic variation in 
humans have shown little association with muscle phenotypes (58; 118).  This has led 
researchers to explore variation in genes involved in the regulation/signaling of 
myostatin.  Two linkage analyses have been performed examining myostatin pathway 
genes with knee strength in humans (55; 56).  Huygens et al. (55) single point linkage 
analysis provided suggestive evidence that GDF8, CDKN1A and MYOD1 may explain a 
portion of the inter-individual variance of knee strength.  However, Huygens and 
colleagues (56) multipoint linkage analysis failed to replicate these findings but did 
observe significant linkage for the CDK2 and RB1 genes as potent quantitative trait loci 
for muscle strength.  While Huygens and colleagues examined genes downstream of 
myostatin (e.g., after myostatin signaling has been initiated), we chose to focus on genes 
upstream of this signaling cascade.  The two candidate genes chosen for the present study 
were follistatin and ACVR2B; follistatin has been shown to be a potent antagonist of 
myostatin (3; 74), capable of binding myostatin and inhibiting its ability to bind to its 
primary receptor, ACVR2B (74; 142).  
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 The molecular basis for the associations observed for the ACVR2B and follistatin 
genes with skeletal muscle phenotypes in the present study is uncertain and cannot be 
addressed by the current study.  However, follistatin has been shown to have a strong 
affinity for myostatin and can completely prevent myostatin receptor activation and 
downstream phosphorylation of Smad3 (3).  Phosphorylation of Smad3, a key step in the 
myostatin cascade in negatively regulating skeletal muscle, induces binding of Smad3 to 
MyoD and represses the activity of the MyoD family of transcription factors resulting in 
inhibition of myoblast differentiation (70; 78). We speculate that perhaps a causal 
mutation yet to be identified within the follistatin haplotype group 3 leads to a decreased 
ability of follistatin to bind and inhibit the activity of myostatin, leading to a greater 
phosphorylation of Smad3, and therefore a reduction in skeletal muscle mass in men.   
In regards to ACVR2B haplotype structure and its observed association with 
muscle strength in women, the absence of myostatin in myostatin null mice has been 
shown to lead to an overall faster and more glycolytic muscle phenotype in these animals 
(40).  The soleus muscle of myostatin null mice display a larger proportion of fast twitch 
type II fibers and a reduced proportion of slow type I fibers compared with wild-type 
animals (40).  Although speculative and without fiber type data in support, perhaps 
ACVR2B haplotype structure influences the ability of myostatin to interact with its 
receptor and therefore impacts the resulting signaling cascade leading to differences in 
fiber type distribution.  Specifically, perhaps myostatin’s interaction with its receptor in 
women homozygous for ACVR2B haplotype group 2, leads to a greater proportion of fast 
twitch muscle fibers, helping to explain the greater level of muscle strength observed in 
these individuals.   
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There is no obvious explanation for the sex differences observed in the present 
study (i.e., a relationship between follistatin and muscle mass in men, and a relationship 
between ACVR2B and muscle strength in women).  Previous candidate gene association 
studies involving skeletal muscle phenotypes by our group (110; 134) and others (18; 
129; 130) have also observed sex-specific differences. Although speculative, perhaps the 
sex differences that have been observed in several studies are partially due to sex-specific 
gene x hormonal environment interactions. 
The present study is not without limitations.  Due to statistical power limitations 
regarding the follistatin haplotype analysis, specific haplotype groupings needed to be 
collapsed in order to increase statistical power.  Specifically, due to the low number of 
both homozygous follistatin haplotype group 2 individuals and homozygous follistatin 
haplotype group 3 individuals, sub-analyses were performed for each of these haplotype 
groupings by creating two groups, carriers of the respective haplotype or non-carriers.  
Another limitation is that this study examines the relationship between only two genes 
with skeletal muscle phenotypes and we don’t do a combined analysis of the two genes.  
Skeletal muscle mass and strength are complex phenotypes and most likely are 
influenced by multiple genes, environmental factors, and gene x environment 
interactions.  To date, variation in the ciliary neurotrophic factor (109), ciliary 
neurotrophic factor receptor (108), vitamin D (111), interleukin-6 (110), androgen 
receptor (134), type I collagen (131), alpha-actinin-3 (19), glucorticoid receptor (66; 
129), insulin like growth factor-1 (66), and insulin like growth factor-2 (66; 115) genes 
have all been shown to be associated with skeletal muscle mass and/or strength.  The 
current study adds the ACVR2B and follistatin genes to a growing list of genes that have 
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been tentatively identified as contributing to inter-individual variation in skeletal muscle 
phenotypes.  The importance of all of these genes will need to be confirmed and the 
interactions among them will also need to be examined. Moreover, for genes with a 
verified influence on muscle, potential interactions with therapeutic strategies (e.g., 
strength training or hormonal therapy) will need to be explored, as the ultimate goal of 
this research is to allow for optimization of individual prescriptions for maintaining 
muscle function throughout the age span. 
The strong role for myostatin in both muscle development and the maintenance of 
muscle mass in adults (82) provides a rationale to address whether genetic variation in 
members of its pathway (e.g., ACVR2B and follistatin) influence muscle phenotypes. 
Although the heritability of both muscle mass and strength have been well established, 
the identification of specific genes and allelic variants contributing to these phenotypes is 
in its infancy (111).  Understanding the genetic factors that underlie these phenotypes 
will require researchers to continue to identify the genes important to muscle phenotypes, 
identify polymorphic variation within those genes, determine the influence of the 
observed genetic variation on muscle phenotypic variation, with subsequent studies 
aimed at assessing the mechanisms and interactions of observed associations and 
developing clinically-relevant strategies for at-risk individuals with low levels of skeletal 
muscle mass and strength. Although the present study is not specifically examining 
sarcopenia, such genetic work may prove important for helping to explain the inter-
individual variation in muscle mass and strength. Considering the continued increase in 
the proportion of older men and women in the U.S. population and the high economic 
cost associated with sarcopenia (61), results from this project and others may allow for 
24   
 
the early identification of individuals genetically susceptible to low levels of muscle mass 
and strength, thus allowing the introduction of interventions prior to the onset of 
associated infirmities. 
In conclusion, this is the first study to explore associations between the haplotype 
structures of the ACVR2B and follistatin genes with skeletal muscle mass and strength 
phenotypes.  These data indicate that the ACVR2B and follistatin loci may contribute to 
the inter-individual variation in skeletal muscle mass and strength.  These results will 
help generate the direction of hypotheses for future studies and in combination with 
previous and future studies will contribute to the growing understanding of the role of 























Hypothesis 1:  Polymorphic genetic variation in a primary myostatin receptor, ACVR2B, 
will be associated with significantly different levels of muscle mass or strength. 
This hypothesis was only partially supported.  ACVR2B haplotype structure was 
significantly associated with skeletal muscle strength in men but not in women.  No 
significant association was found between ACVR2B genetic variation and muscle mass.   
 
Hypothesis 2:  Polymorphic genetic variation in follistatin will be associated with 
significantly different levels of muscle mass or strength. 
This hypothesis was only partially supported.  Follistatin haplotype structure was 
significantly associated with skeletal muscle mass in men but not women.  No significant 
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REVIEW OF LITERATURE 
 
The following review of literature is divided into three main areas and provides 
background information on sarcopenia, myostatin including myostatin related genes, and 
the genetic analysis developed for this dissertation.  Across these three areas the review 
will focus on the following topics:  1) the importance of muscle mass and strength to 
health and function 2) mechanisms of sarcopenia, 3) prevention and treatment of 
sarcopenia through strength training, 4) the heritability of skeletal muscle mass/strength, 
5) candidate gene studies, 6) myostatin, 7) regulation of myostatin-ACVR2B and 
follistatin as candidate genes, 8) background of the genetic analysis-haplotype, 9) 
Haploview software program, 10) sliding window analysis, and 11) TaqMan genotyping 
assays. 
 Importance of Muscle Mass and Strength to Health and Function 
Skeletal muscle mass gradually declines starting at about age 45 years (61) and it is 
estimated that after the fifth decade 6% of muscle mass is lost per decade until the eighth 
decade of life in men (80).  This loss of muscle mass that occurs with healthy aging is 
commonly known as sarcopenia, a Greek term coined by Rosenberg referring to the “poverty 
of flesh” (106) denoting this tissue loss with age.  $18.5 billion dollars was the estimated direct 
healthcare cost attributable to sarcopenia in 2000 and it is currently estimated that ~45% of the 
older population ( > 60 yrs of age) is sarcopenic (61) with sarcopenic women having 3.6 times 
higher rates of disability and men 4.1 times higher rates than non-sarcopenic individuals (8).   
Furthermore, the loss of muscle strength is an independent predictor of mortality in the elderly 
(88; 101).  The negative economic impact of sarcopenic related disability at the societal level is 
clear, while the cost of the reduction in quality of life for these individuals can’t be easily 
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calculated.  By the year 2030 approximately 30% of the United States population will be 
elderly and will potentially experience some health problems as well as loss of independence.  
This loss of independence occurs on many levels, but one undoubtedly important component is 
loss of mobility, due in part to losses in both muscle mass and strength.  Therefore, sarcopenia 
presents a major public health concern to our aging population. 
Many studies have shown a correlation between muscle mass and strength (34; 
37).  Muscle strength has been reported to reach peak values between 25 and 35 yrs of 
age, is maintained or is slightly lower between 40-49 yrs of age, and then is ~12-14 % 
less per decade after 50 yrs of age (71; 77; 87).  Even when corrected for the decreased 
muscle mass that occurs with age, there is significant decline in peak torque, suggesting 
that the quality of skeletal muscle or efficiency of muscle strength per muscle mass is 
reduced.  Reduction in muscle strength is determined by not only a decrease in muscle 
mass but also due to changes in the quality of the muscle.  
 It seems intuitive that loss of muscle quantity, quality, and strength would result 
in a quantifiable loss of function in task performance.  A number of groups have studied 
and quantified this loss of function.  Brown et al. (11) studied 16 elderly (aged 75-88) 
healthy community volunteers and showed that composite lower extremity strength 
correlated with gait speed and negatively correlated with the time required to perform 
five stand-ups.  Wolfson et al. (138) compared the strength, balance, and gait speed of 17 
nursing home residents that had two or more documented falls in the preceding year 
(fallers) with 17 matched non-falling controls.  Ankle and knee flexion and extension 
were significantly weaker in fallers than in controls.  Bassey et al. (7) measured muscle 
strength and the amount and speed of customary walking in a large sample of men and 
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women older than 65 yrs.  They found an age-related decline in muscle strength and a 
significant negative correlation between strength and chosen normal walking speed for 
both sexes.   Fiatarone et al. (34) showed that in frail institutionalized men and women 
over the age of 86 there is a close correlation between the loss of quadriceps muscle 
strength, loss of skeletal muscle mass, and the slowing of gait speed.  These data suggest 
that with advancing age muscle strength is a critical component of walking ability. 
 The New Mexico Study (8) lends further insight into the relationship between 
sarcopenia and function.  Sarcopenic women had 3.6 higher rates of disability, and men 
4.1 times higher rates compared with study participants with normal muscle mass.  There 
were significantly greater risks of use cane or walker and a history of falling in the 
sarcopenic subjects as well.  These odd ratios were significant after adjustments for age, 
race, obesity, income, alcohol intake, physical activity, current smoking, and 
comorbidity.  Thus, the authors concluded that sarcopenia is independently associated 
with important health outcomes and disabilities in this relatively healthy ambulatory 
population. 
Mechanisms of Sarcopenia 
Determinants of sarcopenia are likely to be a combination of both intrinsic factors such 
as hormonal changes, mitochondrial damage due to oxidative stress, denervation, and 
extrinsic/environmental factors, such as nutrition, physical inactivity.  Thus, it follows that the 
etiology of sarcopenia will turn out to be multifactorial (113).  The relative importance of each 
of these factors is extremely complex and variable and has yet to be completely resolved.   
Each area is reviewed below. 
 
29   
 
Hormones and Aging 
 Aging causes loss of many of the anabolic signals to muscle that are present in 
young adulthood. Recent research suggests that there is also an increase in catabolic 
signals with age.  Loss of muscle with age may be caused by the loss of anabolic factors 
such as testosterone and growth hormones as well as an increase in catabolic factors such 
as inflammatory cytokines; or by a combination of the two. 
 Levels of bioavailable “free” testosterone are known to decrease with age.  Cross 
sectional population based studies have shown varying rates of decline.  Van den Beld et 
al. (128)  showed that between the ages of 73-94 there is about a 3% per year decline in 
free testosterone levels.  Cross-sectional and longitudinal data from Harman and 
colleagues (47) on relatively healthy men in the BLSA demonstrated unequivocally that 
testosterone concentrations are not only lower in older men, but that they decline 
progressively with aging, beginning in the third decade of life.  This decrease is thought 
to parallel the decrease in lean muscle mass and the loss of strength that occurs in aging 
men.  Low bioavailable testosterone concentrations have been associated with low fat 
free mass and decreased strength of knee extension (96; 114) and Katznelson and 
colleagues demonstrated that low testosterone concentrations were associated with 
decreased fat free mass in healthy hypogonadal men compared with human adult controls 
(63). 
 Circulating levels of growth hormone (GH) and its peripheral mediator, insulin-
like growth factor-1 (IGF-1), decrease with age (52) and many studies have demonstrated 
that GH levels begin to decline in the fourth decade of life and progressively continue to 
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decline over ensuing years. This loss of GH and IGF-1 is thought to be causally related to 
the loss of muscle mass and strength that occurs with age (42).   
 Interleukin-6 (IL-6) is one of several proinflammatory cytokines.  Under normal 
circumstances in young individuals, its expression is tightly regulated by the interplay of 
several transcription factors and hormonal factors including the secondary sex steroids.  
IL-6 expression increases late in life, this increase is thought to result from loss of the 
normally inhibiting sex steroids.  Ershler and Keller (30) point out that testosterone, 
which diminishes with age, is a key factor that downregulates IL-6 gene expression and 
propose that the age associated increase in IL-6 could help to account for the phenotypic 
changes that occur in the elderly, including decreased lean body mass.  Roubenoff (112) 
has suggested that IL-6 and other cytokines could function through direct catabolic 
effects or, more indirectly by inducing anorexia, lowering GH and IGF-1 concentrations, 
or by triggering loss of muscle cells in the elderly—even in the absence of overt 
inflammatory disease.  Visser and colleagues (132) reported that higher plasma 
concentrations of IL-6 were associated with lower muscle mass and strength in healthy 
older individuals. 
The aging-associated inflammation affecting skeletal muscle also includes 
elevated circulating levels of  tumor necrosis factor-α (TNF-α) as well as the local 
expression of TNF-α by skeletal muscle (97). This age-related increase in circulating 
levels of TNF-α in skeletal muscle may be a contributing stimulus for apoptosis and fiber 
loss.   Chronic exposure of skeletal muscle to TNF-α can cause apoptosis in both 
myoblasts and myofibers.  TNF-α causes existing differentiated muscle fibers to 
degenerate and at the same time limit the ability for regeneration via proliferation and 
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fusion of myoblasts.  Myoblasts exposed to chronically elevated TNF-α have also been 
shown to undergo apoptosis (26; 120). 
 Because sarcopenia develops over many decades, only a small change in the 
balance of muscle protein catabolism and anabolism is needed to effect a large change in 
body composition over such a long time span.  The combination of the withdrawal of 
anabolic stimuli, such as testosterone and growth hormone, and the possible increase in 
catabolic stimuli, such as IL-6 and TNF-α , may thus weave a complex web of signals 
whose ultimate result is a decline in muscle mass and strength that we now recognize as 
sarcopenia (113). 
Oxidative Stress and Mitochondrial Damage 
  Dr. Denham Harman in 1956 (46) developed the Free Radical Theory of Aging.  
The basic tenet of this theory is that reactive oxygen species (ROS) underlie the 
fundamental changes found in aging.  Harman hypothesized a correlation between 
aerobic metabolism, cumulative oxidative damage, and senescence.  Due to the high level 
of oxygen consumption seen in skeletal muscle compared to other tissues along with the 
attention that has been given to mitochondria because of their role in oxidative 
phosphorylation (the electron transport system (ETS) consumes ~ 85% of all the oxygen 
used in the cell)  and the fact that the vast majority of cellular ROS, with some estimates 
as high as 90%, can be traced back to the mitochondria, recent research has begun to 
investigate the role that ROS may play in mitochondrial damage and sarcopenia. 
Mitochondrial DNA (mtDNA) is the only extrachromosomal DNA in mammalian 
cells. The mtDNA contains 37 genes, encoding 13 proteins (all of which are respiratory 
chain subunits), 22 tRNAs, and two rRNAs.  Mutation in the regulatory regions of 
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mtDNA could interfere with replication, transcription, or processing of mitochondrial 
transcripts.  Deletion or mutation of mtDNA has been found to be responsible for 
dysfunction of energy production and an increase in necrosis of skeletal muscle fibers. 
It has been proposed that mtDNA, which encodes a small number of critical 
mitochondrial genes and may be exceptionally sensitive to oxidative damage (14; 21; 
103).  High levels of oxidative damage and mutation in mtDNA have been ascribed to 
location of the DNA near the inner mitochondrial membrane where oxidants are formed, 
lack of protective histones, and lack of DNA repair activity.   Damage to mtDNA by 
mitochondrial oxidants, it has been suggested, may result in faulty mitochondrial 
proteins, decreased oxidative phosphorylation capacity, increased mitochondrial oxidant 
generation, and increased mtDNA damage.  This hypothetical positive feedback loop is 
generally referred to as the “vicious cycle”   
mtDNA somatic mutation   → defective mtDNA-encoded proteins→ 
defective ETS→ generation of mutagenic oxidants→ mtDNA somatic mutation    
This vicious cycle of mutation and oxidant production eventually leads to cellular 
catastrophe, organ failure, and senescence (81). 
McKenzie and colleagues (84) hypothesize that oxidative damage to the 
mitochondrial genome has the potential to trigger a mitochondrial deletion event.  
Accumulation of these mtDNA deletion mutations would cause a decline in the energy 
production of the affected cells, result in abnormal electron transport enzyme phenotypes, 
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and the fibers would no longer be capable of self maintenance, resulting in intrafiber 
atrophy, and ultimately, lead to fiber loss.   
Work by Aiken and colleagues (1) involving rhesus monkeys, rats, and mice have 
proposed the following mechanism for muscle fiber loss with age. An early event is a 
mtDNA replication error that results in the deletion of a large region of the mitochondrial 
genome. This smaller genome apparently out-replicates the wild-type genome, becoming 
the predominant species in an expanding region of the muscle fiber. The high abundance 
of the deletion mutation in a specific region of a muscle fiber results in a focal decline in 
cytochrome c oxidase (COX) activity. A common ETS-abnormal phenotype observed in 
aging skeletal muscle is the complete loss of detectable COX activity (COX-).  The 
nuclear response to this decline in ETS efficiency appears to result in nuclear 
upregulation of mitochondrial biogenesis, further exacerbating the problem and 
producing the COX- phenotype. This process expands along the length of the muscle fiber 
until the resulting energy deficit triggers the fiber atrophy and, eventually, fiber breakage. 
This fiber breakage could produce the fiber loss observed with age.  Therefore given the 
increase in oxidative damage that accumulates with age, it is conceivable mitochondrial 
DNA deletion events that occur as a result of oxidative damage thereby helps to promote 
muscle fiber loss with age, thus sarcopenia. 
Work by Kujoth et al. (68) have also examined mitochondrial DNA mutations and 
their role in cell death.  The researchers showed that mice expressing a proofreading-
deficient version of the mitochondrial DNA polymerase g (POLG) accumulate mtDNA 
mutations and display features of accelerated aging.  The authors cloned the mouse 
POLG locus, PolgA, and used gene targeting in embryonic stem cells to introduce an AC 
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to CT two-base substitution. This mutation results in a critical residue substitution in the 
conserved exonuclease domain of POLG, impairing its proofreading ability.  Transgenic 
mice homozygous for this mutation were generated and given the name D257A. Young 
D257A mice were indistinguishable from wild-type littermates, but long-term follow-up 
revealed a striking premature aging phenotype beginning at ~9 months of age, consisting 
of hair loss, graying, and kyphosis.  Consistent with a causal role for mtDNA mutations in 
sarcopenia, the D257A mice displayed age-related loss of skeletal muscle.  At 3 months 
of age, muscle weight in the D257A mice was similar to that of wild-type mice; at 9 
months of age, however, the mutant mice showed a significant reduction in the weight of 
both gastrocnemius (~10% decrease) and quadriceps (~10% decrease) muscles. 
Therefore, the authors concluded that age-related accumulation of mtDNA mutations is 
likely to contribute to sarcopenia (68). 
Denervation 
If there is a single most important endogenous cause of sarcopenia, it is probably 
the loss of alpha motor neuron input to muscle that occurs with age (12).  This decline of 
muscle innervation may be one of the key events in the sarcopenic process since 
innervation is crucial to the maintenance of muscle mass, as well as strength.  In the 
elderly there is a decrease in the number of functional motor units associated with a 
concomitant enlargement of the remaining units. This motor unit remodeling seems to be 
caused by selective denervation of muscle fibers with re-innervation by axonal sprouting 
from juxtaposed innervated units (10). This process leads not only to a net loss of fibers 
and functional motor units but also an increase in motor unit size (28).  This age related 
net loss of muscle fibers has been demonstrated to be fiber type specific and has been 
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shown to involve a greater loss of fast fiber cross sectional area.  Lexell et al. (76) in a 
comprehensive study of the entire vastus lateralis in 43 male cadavers aged 15-83, 
showed that there is an age related loss in fiber number and based on measurements of 
cross sectional area, there is a selective loss of fast twitch type II fibers as compared to 
slow twitch type I fibers.  The end result is a decrease in the number of fast twitch motor 
units and fast twitch muscle fibers and the skeletal muscle appears to compensate for this 
reduction in motor units by hypertrophy of existing smaller and slower motor units that 
attempt to reinnervate faster fibers and transform them into slower fiber types (25; 28). 
Cycling of Denervation-Reinnervation 
Investigators reason that the normal cycling of denervation-reinnervation that is 
evident in younger muscle is impaired in aged muscle.  Consequently, there is a net effect 
of denervation affecting skeletal muscle of the elderly, which significantly contributes not 
only to the loss of motor units, but also to the loss of muscle fibers that mainly accounts 
for sarcopenia (76).   
The mechanism(s) of the denervation occurring during aging has yet to be fully 
elucidated, however ciliary neurotrophic factor (CNTF) has been identified as an 
important molecule in the survival of motor neurons (94).  Recent research has shown 
that relative to young motor neurons, CNTF production is attenuated in aged peripheral 
nerves (43).  In work performed by Guillet and colleagues (43), a strong correlation was 
established between the decline of CNTF expression and muscle strength measured 
among aged rats.   
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Nutrition-Anorexia 
The concept that there is a physiological decline in food intake from the ages of 
20-80 yr is now well established in both large populations and in highly healthy persons 
(90).  It is well recognized that aging is associated with a decline in food intake and this 
has been termed the "anorexia of aging" and in most cases is an appropriate response to 
the decrease in physical activity that occurs over the lifespan (91).  However 
physiological anorexia in older men and women may outstrip the reduction of physical 
activity, leading to weight loss and sarcopenia in the elderly (89).  Inadequate intake of 
calories, particularly sufficient protein, results in a negative nitrogen balance and muscle 
breakdown and loss. 
For muscle to maintain its mass, the rate of protein synthesis must be in balance 
with the rates of degradation to amino acids in combination with dietary absorption 
maintaining the difference in amino acid utilization.  For sarcopenia to occur, only small 
imbalances between synthesis and degradation over many years are necessary to 
eventually result in a significant loss of muscle mass (92).  With advancing age combined 
with inadequate dietary intake of amino acids can decrease the rates of protein synthesis 
and ultimately exacerbate the onset of sarcopenia.    
The current Recommended Dietary Allowance (RDA) for protein to meet the 
needs of adults over the age of 19 years is 0.8 grams/kg/day.  However, recent studies 
suggest that the protein requirements of older individuals may be higher (~ 1g/kg/day).  
Campbell et al. (16) examined studies in the literature examining nitrogen-balance in 
elderly people and recalculated the balance data using currently accepted values for 
miscellaneous losses.  The conclusion of this retrospective analysis and new balance data 
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presented was that the current RDA is inadequate to meet the dietary protein needs of 
most elderly people.  Campbell (17) then confirmed this conclusion in a study that 
examined the long term consequences of consumption of the protein RDA.  This study 
enrolled healthy elderly men and women and provided the 0.8 gr/kg/day over a 14 week 
period in a metabolic ward.  Using computerized tomography, the researchers 
demonstrated that a significant reduction in the cross sectional area of thigh muscle.  
Thus, the authors concluded that the data suggest that the protein RDA for elderly people 
is not adequate, even while consuming a weight maintenance diet. 
 Physical Inactivity 
 
 The extent to which lifelong activity patterns and training can prevent declines in 
muscle mass and strength has not been prospectively examined (27).  Therefore it is 
difficult to causally determine the relative importance of physical inactivity in the 
development of sarcopenia, especially regarding the cross-sectional nature of many 
studies in this area.  However, it has been well demonstrated that elderly persons who are 
less physically active have less strength and lean mass than do active elderly individuals 
(69; 99) and it is very well known that short term muscle inactivity severely reduces 
muscle mass and strength even in young individuals (133).  A typical example of this is 
bed rest (31).  However, it has been shown that these muscle changes can be counteracted 
by exercise, typically resistance exercise (32), which perhaps provides the most 
convincing evidence of the importance of physical activity and maintenance of skeletal 
muscle mass and strength. 
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Prevention and Treatment of Sarcopenia through Strength Training 
By the year 2030 approximately 30% of the United States population will be elderly 
and will potentially experience some health problems as well as loss of independence.  This 
loss of independence occurs on many levels, but one undoubtedly important component is loss 
of mobility, due in part to losses in both muscle mass and strength.  Therefore, sarcopenia 
represents a major public health concern to our aging population.   Prevention of muscle loss 
before it occurs would be one of the most important interventions we could hope to make.  
Exercise trials have provided some of the most promising data for both prevention and 
treatment of loss of muscle mass and strength.   
Although sarcopenia is a multi-factorial process, decreases in physical activity 
throughout the lifespan may play a key role.  Hunter and colleagues (54) argue the 
reduction of strength and muscle function that occurs with age are mediated by decreases 
in physical activity.  The result is a positive feedback loop as reduced physical activity 
further decreases strength, ease of physical activity, and participation in physical activity.  
These authors state that interrupting this feedback loop is a vital step toward maintaining 
the quality of life and health of an aging population.  A growing body of evidence 
supports resistance training as an effective means of disrupting this deleterious loop.  
Latham et al. in 2004 (72) reviewed the literature on progressive resistance training in 
older adults.  Their analysis of 41 randomized controlled trials revealed that progressive 
resistance training results in improvements in muscle strength and some aspects of 
functional limitation, such as gait speed, in older adults.   
Although some clinicians are reluctant to recommend high-intensity resistance 
training, many reports have shown that resistance training can be performed safely in an 
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elderly population.  Sullivan et al. (122) performed a 10 week study of lower body 
resistance training in a group of 19 recuperating nursing home patients whose mean age 
was 83 years. 1-RM strength increased by 74% and maximum gait speed increased in 
53% of subjects without any adverse effects.  Similarly, Hauer et al. (49) studied 28 
elderly subjects (mean age 81 years) with a history of injurious falls.  These subjects 
performed 12 weeks of lower body resistance training at 70-90% 1-RM and obtained 
increases of 22-87% in 1-RM strength with no training related medical problems.  A 
review of the literature by Fielding (35) demonstrates that a training stimulus of 
appropriate intensity (70-90% of  1–RM) produces gains in muscle size and strength in 
healthy older individuals that are comparable with gains produced in young individuals.  
Work by Ivey and colleagues (59) further solidified this finding.  Eleven young men, 11 
young women, 12 older men, and 11 older women had bilateral quadriceps muscle 
volume measurements performed using magnetic resonance imaging (MRI) before and 
after strength training.  The training consisted of five sets of knee extension exercise 
designed to include a combination of heavy resistance and high volume exercise.  After 
nine weeks of training strength training induced muscle volume changes in the older 
subjects were not significantly different than in the young subjects. 
Perhaps some of the most impressive evidence in support of resistance training in 
the elderly as an efficacious intervention comes from work by Fiatarone and colleagues 
(34) published in JAMA in 1990.  Ten frail, institutionalized volunteers aged ~90 years 
undertook 8 weeks of high-intensity resistance training. Strength gains averaged 174% in 
the 9 subjects who completed training. Mid-thigh muscle area increased 9.0 % and mean 
tandem gait speed improved 48% after training. The authors concluded that high-
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resistance weight training leads to significant gains in muscle strength, size, and 
functional mobility among frail residents of nursing homes up to 96 years of age.  
Work by Lemmer and colleagues (34; 75) have now provided suggestive evidence 
for how much of the age-associated losses in strength and muscle mass can be reversed 
with strength training.  Strength losses assessed from isokinetic peak torque values occur 
at the rate of about 12-14% per decade after the age of about 50 years and strength gains, 
assessed from 1-RM values, of >30% occur within the first couple of months of heavy 
resistance strength training in 65-75 year old men and women (75).  Thus, about two 
months of strength training essentially reverses at least 2 decades of strength loss with 
advancing age.  Similar reversals can be observed with muscle mass, which is lost at a 
rate of about 6% per decade after the age of 50 years and increases by about 12% within 
the first couple of months of strength training (127).  Thus, 2 decades of age-induced 
muscle mass loss can be reversed with only about 2 months of strength training. 
Heritability of Skeletal Muscle Mass and Strength 
Skeletal muscle mass and strength are known to vary among individuals of a 
given age and sex.  Differences in muscle mass and strength between individuals may be 
due to environmental or genetic factors or to both of these factors.  Heritability (h2) refers 
to the proportion of the total variation that can be attributed to genetic effects (Vg/Vtot). 
Assessment of heritability is based on the basic genetic model that the total variation 
(Vtot) in traits such as muscular strength/muscle mass is partitioned into genetic (Vg), 
common environmental (Vc) and individual-specific environmental (Ve) variation 
components (Vtot = Vg + Vc + Ve).  The most commonly used strategy to identify 
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genetic and environmental contributions to muscle strength and mass has been twin 
studies. 
Arden et al. (5) examined the heritability of lean body mass in healthy 
postmenopausal women in 227 pairs of monozygotic (MZ) twins and 126 dizygotic (DZ) 
twins and concluded that genetic factors explain about half (.52) of the total variance of 
lean body mass in this cohort. Forbes et al. (36) found a heritability of 70% in 49 MZ and 
38 DZ twin pairs.  Seeman et al. (117) estimated the genetic component of lean body 
mass explained 80% of the total variance found in a twin study of pre and post 
menopausal women and concluded that greater muscle mass is likely to be determined by 
genes regulating tissue size.   
Muscle strength is also a highly heritable phenotype.   Arden et al. (5) examined 
the heritability of lean body mass in healthy postmenopausal women in 227 pairs of MZ 
twins and 126 DZ twins and concluded that genetic factors explain about one third (.30) 
of the total variance in grip strength in this cohort.  Reed et al. (102) reported that genetic 
factors accounted for 65% of the variance in grip strength in a study of 260 MZ and DZ 
male twins from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study who 
were 59-69 yr of age, even after adjusting for body weight, height and age.    
Most recently, Huygens et al. (57) reported that heredity accounted for up to 90% 
of the inter-individual variation in muscle mass and ~60% in strength providing further 
evidence that genetic factors make important contributions to these muscle phenotypes. 
Although the heritability values for both muscle mass and strength have been well 
established, the identification of specific genes and allelic variants contributing to these 
phenotypes is in its infancy (111).    
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Candidate Gene Studies 
With the completion of the human genome project (HGP), a high-quality 
reference sequence of the gene rich portion of the human genome is now available.  This 
has opened up the possibility to systematically identify all possible gene variants in 
different human populations, associate their presence with individual phenotypes, 
including disease susceptibility, and determine the functional impact of such variation.  
The most abundant source of genetic variation in the human genome comprises single 
nucleotide polymorphisms (SNPs) (121).  Associating SNPs with human disease 
phenotypes has great potential for direct clinical application by providing new and more 
accurate genetic markers for diagnostic and prognostic purposes, and possibly novel 
therapeutic targets (121). 
Association studies using a candidate gene approach looks for a statistical 
correlation between a specific genetic variant and a disease.  The candidate gene 
approach can be defined as the study of genetic influences on a complex trait by: 
generating hypotheses about, and identifying candidate genes that might have a role in, 
the etiology of the disease; identifying variants in or near those genes that might either 
cause a change in the protein or its expression, or be in linkage disequilibrium (LD) with 
functional changes; genotyping the variants in a population; and then using statistical 
methods to determine whether there is a correlation between those variants and the 
phenotype.  Given the possible promising aspects of association studies, association 
studies with candidate genes have been wide to study the genetic aspects of complex 
diseases. Before 1992, less than 10 genetic association studies were published per year, 
but by 2000, the number had increased to 120 (51).    
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Myostatin  
Bullough (13) in 1962 proposed that tissue size is controlled by the activity of 
negative growth regulators that he dubbed chalones.  According to this hypothesis, 
individual tissues secrete distinct chalones, which circulate throughout the body and act 
to inhibit the growth of the tissue producing the specific chalone.  Recent work suggests 
that at least one tissue may, in fact, utilize this general type of regulatory mechanism to 
control tissue mass.  This tissue is skeletal muscle, and the mediator appears to be 
myostatin. The identification of myostatin as a negative regulator of muscle growth has 
raised many important questions about the control of muscle growth.  Understanding the 
mechanisms by which myostatin regulates muscle mass will be critical not only for 
understanding the control of tissue size in general but also for developing new strategies 
for increasing muscle growth for human therapeutic applications (73).    
 First reported in 1997 by McPherron et al. (85), myostatin (growth and 
differentiation factor-8) was identified in mice as a transforming growth factor-β (TGF-
β) family member that acts as a negative regulator of skeletal muscle growth. Soon after 
the initial report of myostatin’s discovery, several groups identified mutations in the 
myostatin gene in naturally-bred “double-muscled” cattle breeds (41; 86).  Perhaps the 
most exciting research involving genetic variation within the myostatin gene comes from 
a case report published in JAMA in 2004.  Scheulke and colleagues (116) reported a rare 
and novel variation in the myostatin gene in a young child, who when born appeared 
extraordinarily muscular, with protruding muscles in his thighs and upper arms.  Results 
from ultrasonongraphy when the child was 4.5 years of age showed that cross-sectional 
plane of the patients quadriceps muscle was 7.2 SD above the mean for 10 age and sex 
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matched controls.  All three exons and flanking intronic regions were sequenced and 
although no mutations were detected in the coding region a g-a transition in intron 1 was 
discovered and present in both alleles of the patient.  This g-a transition results in a 108 
base pair insertion adding a single lysine residue followed by a premature termination 
codon giving rise to a severely truncated protein.  The authors attempted to measure 
myostatin levels in the patient’s serum but failed to detect any.  The authors concluded 
that the results strongly indicated that the patient has a loss of function mutation in the 
myostatin gene.  This suggests the inactivation of myostatin has similar effects in 
humans, mice, and cattle, providing further evidence for a critical role for myostatin in 
muscle development in humans, and thus establishing myostatin as the key target it has 
become for muscle researchers. 
Despite myostatin’s remarkable influence on skeletal muscle and the well-
established effect of myostatin gene mutations in double-muscled cattle breeds, studies of 
common myostatin genetic variation in humans have shown little association with muscle 
phenotypes.  Ferrell and coworkers (33) identified several polymorphisms in the human 
myostatin gene, with six nucleotide changes observed, of which five are predicted to lead 
to amino acid sequence changes, but in follow-up work by that group and others only 
minor associations have been observed for the most common of these polymorphisms 
with muscle mass or strength (58; 118).  For example, comparisons of myostatin 
variation, in two of the variants found to be common (A55T) and (K153R), in those who 
were rated in the top two categories to those who were rated in the bottom two categories 
for muscle mass increase in response to strength training showed no significant 
relationship between genotype and response to training (26; 33).  Only suggestive 
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associations of the K153R polymorphism with muscular strength have been reported for 
older females.  Seibert et al. (118) investigated polymorphism variation in the myostatin 
gene in a cohort of 286 older women and state that their data suggest an association of the 
R153 allele with lower strength in high-functioning older women.  Finally, work by Ivey 
et al. (58) examined the effect of myostatin genotype on the hypertrophic response to 
heavy resistance strength training and  myostatin genotype (K153R) did not explain the 
hypertrophic response to strength training when all 32 subjects were assessed.    
Myostatin Structure/Function 
 Myostatin is synthesized in skeletal muscle as a 376 amino acid propeptide which 
gives rise to a 15kDa active, processed, and mature protein.  Structurally, it contains all 
the characteristic features of the TGF-β family, such as a proteolytic processing signal 
site and an active carboxy terminal region.  Myostatin exists as a large, latent complex 
with other proteins, including its propeptide. The function of myostatin was elucidated by 
gene targeting studies in mice (85).  Mice carrying a deletion of the portion of the gene 
encoding the C-terminal domain of myostatin were shown to have dramatic and 
widespread increases in skeletal muscle mass, with individual muscles weighing about 
twice as much as those of wild type mice.   
Regulation of Myostatin-ACVR2B and Follistatin as Candidate Genes 
 Identifying how myostatin influences skeletal muscle and what processes regulate 
myostatin expression and activity have dominated the myostatin literature in the past few 
years.  Similar to other TGF-β family members, myostatin is synthesized as a precursor 
protein that undergoes two proteolytic processing events in order to generate the 
biologically active molecule.  The first event removes the N-terminal signal sequence, 
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most commonly referred to as the propeptide, and the second generates the C-terminal 
fragment which possesses receptor binding activity and is the biologically active species. 
 Myostatin exists as a large latent complex, including its propeptide.  Following up 
their initial discovery, Lee and McPherron (74) demonstrated that activin type II 
receptors are involved in myostatin signaling.  Myostatin binding to ACVR2B receptors 
was specific and saturable, and transgenic mice with increased muscle expression of a 
dominant negative form of ACVR2B had increased muscle weights, with individual 
muscles weighing up to 125% more than those of control nontransgenic animals.  These 
results showed that expression of a truncated form of ACVR2B lacking the kinase 
domain and placed downstream of a skeletal muscle-specific myosin light chain 
promoter/enhancer can cause increases in muscle mass similar to those seen in myostatin 
knockout mice.  In vitro work demonstrated that the propeptide blocked myostatin 
binding to its receptor.  In vivo work by Lee and McPherron (74) showed that increased 
expression of the propeptide in transgenic mice resulted in increased muscle mass, thus, 
the propeptide acts as a myostatin inhibitor. 
 In addition to the propeptide, other proteins have also been shown to be capable 
of binding and inhibiting the activity of the myostatin C-terminal dimer.  Several studies 
suggest that follistatin can function as a potent myostatin antagonist and plays an 
important role in vivo.  First, follistatin is capable of blocking myostatin activity in both 
receptor binding and reporter gene assays (74; 142).  Secondly, genetic studies in mice 
have shown that overexpression of follistatin in muscle can cause dramatic increases in 
muscle growth.  Lee and McPherron (74) generated transgenic mice which the myosin 
light chain promoter/enhancer was used to drive the expression of follistatin and dramatic 
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effects on skeletal muscle were seen.  In one animal muscle weights were increased by 
194-327% relative to control animals; thus it appears, follistatin appears to be a potent 
myostatin antagonist (74).   
With the identification of ACVR2B as the primary myostatin receptor and the 
myostatin propeptide and follistatin as negative regulators of myostatin activity, Lee and 
McPherron (74) put forth the following model of myostatin regulation in 2001: the 
myostatin C-terminal dimer remains in a latent complex with the inhibitory propeptide. 
This latent complex can be further negatively regulated by binding with follistatin, and 
upon release of the negative regulators, myostatin is free to signal through its receptors, 
acting primarily through ACVR2B.    
Downstream Targets 
Upon activation from its latent state, the myostatin C-terminal dimer is capable of 
binding to its receptor and activating a signal transduction cascade in the target cell.  
Myostatin signaling results in an upregulation of p21 which is an inhibitor of Cdk2.  This 
causes a hypophosphorylation of retinoblastoma and a cell cycle arrest (G1) in 
proliferating myoblasts.  Thus myoblast number and, hence, fiber number is regulated by 
myostatin (125).  Myostatin can also inhibit differentiation by upregulation of Smad 3 
proteins that bind to MyoD.  This interaction represses MyoD transcriptional activity.  As 
a result several regulatory factors are downregulated, which results in improper cell cycle 
withdrawal and inhibition of myoblast differentiation (70).  In embryonic myogenesis, 
myostatin regulates myoblast number. In adult muscle, myostatin is specifically 
expressed in the regenerative satellite cells and myostatin null mice have greater numbers 
of both satellite cells per muscle fiber and activated satellite cells (82).   
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Background of the Genetic Analysis-Haplotype 
Variation in the human genome sequence plays a powerful but poorly understood 
role in the etiology of common diseases.  A comprehensive search for genetic influences 
on disease would involve examining all genetic differences in a large number of affected 
individuals and controls.  It may eventually become possible to accomplish this by 
complete genome sequencing.  In the meantime, it is increasingly practical to 
systematically test common genetic variants for their role in disease; such variants 
explain much of the genetic diversity in our species (2). 
 Systematic studies of common genetic variants are facilitated by the fact that 
individuals who carry a particular single nucleotide polymorphism (SNP) allele at one 
site often predictably carry specific alleles at other nearby variant sites. This correlation is 
known as linkage disequilibrium (LD); a particular combination of alleles along a 
chromosome is termed a haplotype (2).   
Linkage disequilibrium plays a central role in association studies for identifying 
genetic variation responsible for common diseases (67; 93; 104; 137).  The number of 
SNPs required for an association study depends on the pattern of LD.  Recent studies 
showed that LD pattern varies greatly across the human genome with some regions of 
high LD interspersed by regions of low LD (22; 23; 38; 62; 95).  These high LD regions 
are referred to as blocks in the literature. Only a small number of characteristic "tag" 
SNPs is sufficient to capture most of the haplotype structure of the human genome in high 
LD regions (62; 95). Thus, genotyping efforts could be greatly reduced without much loss 
of power for association studies (38; 140). 
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The correlations between causal mutations and the haplotypes on which they 
arose have previously served as a tool for human genetic research: first finding 
association to a haplotype, and then subsequently identifying the causal mutation(s) that 
it carries. This was pioneered in studies of the HLA region, extended to identify causal 
genes for mendelian diseases for example, cystic fibrosis (64) and diastrophic dysplasia 
(48), and most recently for complex disorders such as age-related macular degeneration 
(29; 45; 65).     
Haploview-Software Program 
 Given the increase in the number of association studies and the enormous amount 
of public genotype data from HapMap, tools for analyzing, interpreting and visualizing 
these data are of critical importance to researchers (6).  The software program Haploview 
is designed to provide a number of tools for haplotype analysis.  Haploview generates LD 
information, haplotype blocks, and population frequencies in a user friendly format.   
 Haploview calculates several pairwise measures of LD and the user has the option 
to select one of several commonly used block definitions (6; 38; 135).  Alternatively, the 
user may manually select groups of markers for subsequent haplotype analysis.  Once 
groups of markers are selected (either automatically or manually), the program generates 
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Background of the ACVR2B haplotype structure 
HapMap database research into the haplotype structure of the genome sequence 
surrounding the myostatin receptor gene, ACVR2B, has revealed the following haplotypes: 
 Snp1 Snp3 Snp5 Snp8 Snp10 Snp11 Snp14 Snp15 Snp16 Freq 
Hap 1 A T T T A A A T T 0.615 
Hap 2 C C C C G G C C G 0.273 
Hap 3 C C C C G A A T G 0.05 
Hap 4 A T T T A G A T T 0.034 
Hap 5 C C C C A G C C G 0.01 
 
By genotyping SNP 8 (rs: #2268757), the majority of the information of this 
haplotype (Hap) is gained by creating two related groups.  Hap1 (.615) along with Hap 4 
(.034) can be considered one group due to their high degree of similarity, sharing eight of 
nine alleles,  and then Hap 2 (.273),  Hap 3 (.05), and Hap 5 (.01) can be considered a 
second haplotype group, sharing a minimum of five of nine alleles to a maximum of eight 
of nine alleles  
Background of Follistatin haplotype structure 
HapMap database research into the haplotype structure of the genome sequence 
surrounding the follistatin gene has revealed the following haplotypes: 
  Snp1 Snp2 Snp3 Snp4 Snp5 Snp6 Snp7 Freq 
Hap 1 A C C C T A T 0.367
Hap 2 A C C T C A C 0.217
Hap 3 A A T C T A C 0.20 
Hap 4 G C C C T G T 0.133
Hap 5 G C C C T A T 0.042
 
Sliding Window 
One issue inherent in haplotype association studies is haplotype complexity.  
Although haplotypes may be more informative than single markers, the power of 
haplotype analysis is reduced by the potentially large number of haplotypes that need to 
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be studied.  A statistical approach known as the “sliding window” has been developed to 
address this issue (9; 20; 126; 141).  The sliding window helps to focus on the candidate 
region of interest and assess evidence for association within each window, helping to 
reduce the dimensionality of haplotype analysis (141). The sliding window approach 
serves two purposes.  First, the number of haplotype groups in each window may be 
significantly less than that in the whole region, so the association analysis involves fewer 
groups and likely has better power to detect an association between phenotype and 
haplotype.  Second, it is anticipated that associations near true causal variants are 
stronger than those in other regions.    Therefore, given the complexity of follistatin 
haplotype groups, by using SNPs 2, 3, 4, and 5, noted by the grey shading above, as the 
window for analysis regarding this haplotype in order to create three haplotype groups 
rather than five groups.  The rationale for inclusion of SNPs 2, 3, 4, and 5 is that all four 
of these SNPs fall within the follistatin gene, therefore any true causal variants within the 
follistatin gene would be linked to one of the three haplotype groups analyzed.   
By genotyping SNP 2 (rs: # 3797297) Hap 3 is separated from the rest of the haplotypes 
and genotyping SNP 4 (rs: #12152850) separates Hap 2 from the remaining haplotypes 
creating a final group of Hap 1, Hap 4, and Hap 5 that share a minimum of four of six 
alleles. 
Taqman Genotyping Assays 
 
Candidate gene studies are one of the most widely used approaches in the 
dissection of the genetic basis of disease. High-throughput methods for genotyping single 
nucleotide polymorphisms are necessary to perform large-scale association studies (83).  
Genotyping of SNPs in the present study was performed using the 5' nuclease allelic 
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discrimination or TaqMan assay (79) for high-throughput genotyping. In this method, the 
regions flanking the polymorphisms, typically 100 base pairs, are amplified in the 
presence of two probes each specific for one or the other allele. Probes have a fluor, 
called a "reporter," at the 5' end but do not fluoresce when free in solution because they 
have a "quencher" at the 3' end that absorbs fluorescence from the reporter. During 
polymerase chain reaction (PCR), the Taq polymerase encounters a probe specifically 
base-paired with its target and unwinds it. The polymerase cleaves the partially unwound 
probe and liberates the reporter fluor from the quencher, thereby increasing net 
fluorescence.  In each PCR cycle, the cleavage of one or both allele-specific probes 
produces an exponentially increasing fluorescent signal by freeing the 5' fluorophore 
from the 3' quencher.  The presence of two probes, each labeled with a different fluor, 
allows one to detect both alleles in a single tube. Moreover, because probes are included 
in the PCR, genotypes are determined without any post-PCR processing, a feature that is 
unavailable with most other genotyping methods (98). 
The TaqMan SNP genotyping assay is read at the PCR endpoint.  DNA samples 
are genotyped simultaneously on a 96 well plate and genotype calls for individuals are 
made by plotting the normalized intensity of reporter dyes in each sample well on a 
scatter plot.  A clustering algorithm in the data analysis software assigns individual 
sample data to a particular genotype cluster (24). 
Taqman SNP Genotyping Assays provide a number of significant technological 
advances (24): they require only a single enzymatic step, all assays use universal 
reactions and thermal cycling conditions, the location of primers is flexible in the region 
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surrounding the SNP site, and they are close-tubed assays and require no post PCR 
processing. 
Summary 
In summary, skeletal muscle mass gradually declines starting at about age 45 
years and it is estimated that after the fifth decade 6% of muscle mass is lost per decade 
until the eighth decade of life in men (80).  This loss of muscle mass, referred to as 
sarcopenia (106), has been associated with an increased risk of falls, hip fractures, 
functional decline, and mortality (4; 60; 88; 101).  Skeletal muscle mass and strength are 
known to vary among individuals of a given age and sex.  Heritability studies have shown 
that genetic factors can account for up to 90% of the inter-individual variation in muscle 
mass (57) and ~65% in strength (102) providing evidence that genetic variation makes 
important contributions to these muscle phenotypes.  Myostatin, a negative regulator of 
skeletal muscle (73), has been shown to play a key role in both muscle development and 
the maintenance of muscle mass (41; 70; 74; 82; 85; 86; 116). However, variation within 
this gene has not been consistently associated with skeletal muscle mass nor muscle 
strength (33; 58; 118).  Therefore, to further understand the inter-individual difference 
seen in muscle mass and strength research studies examining genetic variation in 
physiologically relevant candidate genes among myostatin related genes are needed to 
explore associations with skeletal muscle related phenotypes.  Two genes whose variation 
has yet to be examined and explored with these phenotypes are follistatin, a known 
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APPENDIX A: Limitations of the Study 
Delimitations 
1.  The scope of this study will be delimited to 315 Caucasian males and 278 Caucasian 
females aged 19-90 yr. from the Baltimore Longitudinal Study of Aging (BLSA).  The 
results are expected to apply only to populations with similar characteristics. 
2. Variables such as age, height, and weight may have effects on muscle mass and 
strength.  Therefore, statistical control for these variables was applied where appropriate. 
3.  Total body fat and soft tissue fat free mass (FFM) and total leg fat and FFM (both legs 
combined) was assessed by dual-energy X-ray absorptiometry (DEXA) (model DPX-L 
Lunar Radiation, Madison, WI). 
4.  Peak torque (strength) was measured using the Kinetic Communicator isokinetic 
dynamometer (Kin-Com model 125E, Chattanooga Group, Chattanooga, TN). 
5.  Genomic DNA was prepared from the EDTA-anticoagulated whole blood samples by 
standard salting-out procedures (Puregene DNA Extraction, Gentra Systems Inc.).  
6. Genotyping of SNPs was performed using the 5' nuclease allelic discrimination or 
TaqMan assay for high-throughput genotyping.  Fluorescence in each well was measured 
using an ABI 7300 Real Time PCR System machine (Perkin Elmer, Applied Biosystems 
Division).  Analysis of raw data to determine genotypes was performed by the ABI 7300 
Sequence Detection System software.   
8.  The International HapMap Project website’s graphical genome browser was used to 
navigate to the particular regions surrounding the candidate genes of interest and retrieve 
HapMap genotype data for all genotyped markers in the selected regions in a format 
accepted by the software program Haploview.  Haploview calculated pairwise measures 
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of linkage disequilibrium (LD) among the polymorphisms in each region and created 
haplotype blocks based on the definition of haplotype block provided by Gabriel and 
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Limitations 
1.  The subjects in the study were generally healthy Caucasian volunteers from the 
Baltimore Longitudinal Study of Aging and not randomly selected from the general 
population.   
2.  Subjects self reported physical activity levels.  Because physical activity was not 
directly measured the accuracy of these reports can not be verified.  Inaccurate self 
reporting of physical activity could have confounded the results of this study. 
3.  Dietary intake and nutritional profiles of the subjects was not measured.  Differences 
in caloric and macronutrient intake could have confounded the results of this study. 
4.  This study examines the relationship between only two genes with skeletal muscle 
phenotypes and combined association of these two genes was not assessed.   
4.  Genotypes other than the three SNPs genotyped in the present study that have 
previously been associated with muscle mass and strength were not genotyped or 
controlled for their potential influence on muscle phenotypes. 
5.  Due to statistical power limitations regarding the follistatin haplotype analysis, 
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APPENDIX B: Definitions 
Allele: one of a pair of alternative forms of a gene that occur at a given locus in a 
chromosome. 
Genome: the total set of genes in a nucleus of a cell. 
Genotype: the genetic makeup of an individual.  It may also apply to a specific locus or 
to a combination of alleles. 
Haplotype: a set of closely linked genetic markers present on one chromosome which 
tend to be inherited together. 
Haploview: a software program designed to provide a number of tools for haplotype 
analysis. 
Heritability: refers to the proportion of the total variation in a phenotype that can be 
attributed to genetic effects or the degree to which a given trait is controlled by 
inheritance.   
Linkage Disequilibrium: the nonrandom association between two or more alleles such 
that certain combinations of alleles are more likely to occur together on a chromosome 
than other combinations of alleles. 
Loss-of Function Mutation: a mutation that impairs or abolishes gene expression, or the 
function of a gene product. 
Sarcopenia: a condition characterized by the loss of muscle mass, muscle strength, and 
muscle quality with aging. 
Single Nucleotide Polymorphism: a DNA sequence variation involving the substitution 
of one nucleotide with a single different nucleotide. 
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Sliding Window Analysis: a statistical approach that helps to focus on the candidate 
gene region of interest and assesses evidence for association within each window, helping 
to reduce the dimensionality of haplotype analysis. 
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APPENDIX C: Statistical Power Analysis 
 
Statistical power analyses 
 Statistical power calculations were estimated for haplotype association with both 
muscle mass and strength phenotypes.  These analyses were performed using effect size 
and standard deviation data obtained from previously published work.  The effect size of 
2.5 kg for FFM differences and the effect size of 11 N·m for skeletal muscle strength 
differences was chosen based on previous work. Sowers et al. (119) demonstrated in 
women that a loss of 2.5 kg of lean mass resulted in lower levels of functioning, slower 
walking velocity, and less leg strength.  The value of 2.5 kg for FFM reflects a minimum 
difference we expect to see or consider comparable to previous studies that have shown 
losses in function associated with a 2.5 kg loss of lean mass.  Hughes et al. (53) 
demonstrated that 11 N·m or ~12% of knee extensor strength is lost per decade in older 
women.   Given the high correlation of low muscle strength to impaired physical function 
(7; 11; 34; 138) we feel a minimum difference in skeletal muscle strength comparable to 
that which is lost per decade in older women is a physiologically important difference to 
expect. 
The subject numbers in Table 1 reflects the minimum number of subjects needed 
for the analysis at 80% power for both mass and strength phenotypes.  For FFM 
differences, the minimum number of subjects required is ~ 47 in each group and a 
minimum number of ~58 for skeletal muscle strength is required with an alpha level at 
0.05 and a power level of 0.80 (Table 1).  
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Table 1.  Calculation results to determine number of subjects and statistical power 

















 Mass2  
  




11 21 0.523 0.05 0.80  58 
 1Values in unit difference between groups. 
 2 Kg (Total Muscle Mass) 
 3 N·m (Knee extensor peak torque) 
 











 Mass2  
  




10 21 0.05 1.0  
 1Values in unit difference between groups. 
 2 Kg (Total Muscle Mass) 
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APPENDIX E- Tables 
 
Table A.  Concentric knee extensor peak torque values in Follistatin haplotype 
group 1 homozygous carriers, haplotype group 1 heterozygous carriers, and non-








Groups 1 & 2 
Heterozygous 
Haplotype 









171.1 ± 3.6  
 
(125) 
168.7 ± 4.7 
 
(73) 
173.7 ± 4.5  
 
(79) 







117.8 ± 2.3 
 
(122) 
112.6 ± 3.1 
 
(67) 
117.0 ± 2.9 
 
(78) 








111.4 ± 2.8 
 
(94) 
111.5 ± 3.8 
 
(52) 
111.2 ± 3.7 
 
(57) 







74.2 ± 1.8 
 
(94) 
72.2 ± 2.5 
 
(50) 
69.9 ± 2.3 
 
(55) 




Data are least square means ± SE.   Age and height were included in the model as significant 
covariates.  
 
Table B:  Subject characteristics for Follistatin haplotype group 2 carriers and non-





Haplotype Group 2 
Non-Carriers of 
Haplotype Group 2 
 
P-value 
N 97 218  
Age (y) 62.8 ± 1.7 62.2 ± 1.1 0.773 
Height (cm) 175.4 ± 0.8 176.6 ± 0.5 0.195 
Weight (kg) 83.9 ± 1.3 84.4 ± 0.9 0.777 
WOMEN 
N 88 190  
Age (y) 56.0 ± 1.7 57.8 ± 1.2  0.388 
Height (cm) 164.0 ± 0.7 162.9 ± 0.5 0.234 
Weight (kg) 68.7 ± 1.3 66.9 ± 0.9 0.258 
Data are means ± SE.  
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Table C:  Soft tissue FFM variables by carriers and non carrier of haplotype group 










  MEN   
Total Body FFM (kg) 
(N) 
57.3 ± 0.5  
(97) 
56.9 ± 0.3  
(218) 
 0.487 
Total Leg FFM (kg) 
(N) 
16.8 ± 0.3  
(88) 




Total Body FFM (kg) 
(N) 
39.8 ± 0.4 
(88)  
39.4 ± 0.3  
(190) 
0.299  
Total Leg FFM (kg) 
(N) 
11.4 ± 0.3  
(81) 
11.3 ± 0.2 
(174) 
 0.739 




 Table D:  Concentric knee extensor peak torque values in carriers and non-carriers 











Concentric (N·m, 30º/sec) 
(N) 
172.2 ± 3.9 
(105) 
171.6 ± 2.7  
(211) 
 0.917 
Concentric (N·m, 180º/sec) 
(N) 
115.0 ± 2.6 
(98) 




Concentric (N·m, 30º/sec) 
(N) 
111.7 ± 3.0 
(84)  
111.1 ± 2.1  
(165) 
0.864  
Concentric (N·m, 180º/sec) 
(N) 
71.7 ± 1.9  
(82) 
72.3 ± 1.4 
(163) 
 0.819 
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Table E:  Concentric knee extensor peak torque values in carriers and non-carriers 











Concentric (N·m, 30º/sec) 
(N) 
173.2 ± 3.9 
(107) 
171.1 ± 2.8  
(209) 
 0.648 
Concentric (N·m, 180º/sec) 
(N) 
116.8 ± 2.5 
(104) 




Concentric (N·m, 30º/sec) 
(N) 
111.4 ± 3.8 
(96)  
111.4 ± 2.2  
(153) 
0.948  
Concentric (N·m, 180º/sec) 
(N) 
69.9 ± 1.8  
(94) 
73.4 ± 1.4 
(151) 
 0.13 




Table F. Soft tissue FFM variables for Follistatin haplotype group 3 homozygous 
carriers, haplotype group 3 heterozygous carriers, and non-carriers of haplotype 









Groups 3 & 1 
Heterozygous 
Haplotype 









56.5 ± 1.9  
(7) 
56.1 ± .5 a 
(83) 
57.0 ± 1.0  
(21) 
57.4 ± .3 b 
(204) 
 a vs b 0.045 
Total Leg FFM 
(kg) 
(N) 
19.1 ± 1.4 a 
 
(4) 
16.6 ± 0.7 b 
 
(72) 
15.8 ± 0.7 c 
 
(17) 
17.5 ± 0.2 d 
 
(187) 
   a vs b 0.10 
a vs c 0.041 
b vs d 0.031 





39.8 ± 0.9 
(17) 
39.8 ± 0.4 
(65) 
39.2 ± 0.7 
(25) 
39.3 ± 0.3 
(171) 
0.738 
Total Leg FFM 
(kg) 
(N) 
11.8 ± 0.6 
 
(14) 
11.7 ± 0.3  
 
(61) 
10.8 ± 0.5 
 
(22) 
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Table G:  Subject characteristics by Follistatin (rs: # 3797297) genotype for 






  MEN   
N 199 104 12  
Age (y) 61.8 ± 1.2 64.1 ± 1.6 57.2 ± 4.8 0.28 
Height (cm) 176.2 ± .5 176.3 ± .7 176.6 ± 2.2 0.976 
Weight (kg) 84.7 ± .9 83.9 ± 1.3 80.3 ± 3.7 0.505 
  WOMEN  P-value 
N 173 91 20  
Age (y) 57.7 ± 1.2  55.6 ± 1.7  58.3 ± 3.6 0.428 
Height (cm) 163.6 ± .5 162.9 ± .7 161.7 ± 1.5 0.99 
Weight (kg) 67.2 ± 1.0 67.5 ± 1.3 68.3 ± 2.8 0.929 
Data are means ± SE.   
 
Table H: Soft tissue FFM variables by Follistatin (rs: # 3797297) genotype in 
Caucasian Men and Women.  
Genotype Group 








    MEN  
 
    
Total Body FFM (kg) 
(N) 
57.4 ± 0.3 a 
(199) 
56.3 ± 0.5 b 
(104) 
57.4 ± 1.4  
(12) 
a vs b 0.067 
Total Leg FFM (kg) 
(N) 
17.6 ± 0.2 a 
(182) 
16.5 ± 0.3 b 
(89) 
17.4 ± 1.0 
(9) 
a vs b 0.004 
  WOMEN   
Total Body FFM (kg) 
(N) 
39.4 ± 0.3 
(173) 
39.6 ± 0.4 
(91) 
39.7 ± 0.8 
(20) 
0.832 
Total Leg FFM (kg) 
(N) 
11.2 ± 0.2 
(160) 
11.5 ± 0.2 
(84) 
11.8 ± 0.6 
(17) 
0.482 
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Table I: Concentric knee extensor peak torque values by Follistatin (rs: # 3797297) 

















170.4 ± 2.8 
 
(205) 
173.3 ± 4.0 
 
(101) 







115.8 ± 1.8 
 
(196) 
117.5 ± 2.6 
 
(98) 










111.6 ± 2.2 
 
(156) 
111.8 ± 3.0 
 
(84) 







73.7 ± 1.4 
 
(154) 
69.7 ± 1.9 
 
(82) 




Data are least square means ± SE.  Age and height were included in the model as significant 
covariates. 
 
Table J:  Subject characteristics by Follistatin (rs: #12152850) genotype for 






  MEN   
N 225 91 4   
Age (y) 61.6 ± 1.1 a 63.0 ± 1.8 b 77.2 ± 8.3 c a vs c 0.065 
b vs c 0.098 
Height (cm) 176.6 ± .5 a 175.7 ± .8 b 167.7 ± 2.2 c a vs c 0.019 
b vs c 0.037 
Weight (kg) 84.7 ± .9 83.9 ± 1.3 80.3 ± 3.7 0.505 
  WOMEN   
N 205 84 10   
Age (y) 56.8 ± 1.1  56.0 ± 1.8 59.7 ± 5.2 0.774 
Height (cm) 163.2 ± .5 164.2 ± .7 163.2 ± 2.1 0.513 
Weight (kg) 66.9 ± .9 68.7 ± 1.4 67.2 ± 3.9 0.556 
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Table K: Soft tissue FFM variables by Follistatin (rs: #12152850) genotype in 
Caucasian Men and Women.  
Genotype Group 








    MEN  
 
    
Total Body FFM (kg) 
(N) 
57.0 ± 0.3 a 
(225) 
57.0 ± 0.5 b 
(91) 
65.2 ± 2.4 c 
(4) 
a & b vs c 0.001 
Total Leg FFM (kg) 
(N) 
17.4 ± 0.2  
(199) 
16.9 ± 0.3  
(82) 
17.4 ± 1.4 
(4) 
 0.501 
  WOMEN   
Total Body FFM (kg) 
(N) 
39.5 ± 0.2 
(205) 
39.9 ± 0.4 
(84) 
39.2 ± 1.1 
(10) 
0.668 
Total Leg FFM (kg) 
(N) 
11.8 ± 0.7 
(186) 
11.4 ± 0.3 
(76) 
11.3 ± 0.2 
(10) 
0.82 




Table L: Concentric knee extensor peak torque values by Follistatin (rs: #12152850) 















172.1 ± 2.7 
 
(223) 
171.4 ± 4.1 
 
(96) 







117.6 ± 1.7 
 
(218) 
114.5 ± 2.7 
 
(89) 








110.6 ± 2.1 
 
(182) 
113.0 ± 3.1 
 
(82) 







71.6 ± 1.4 
 
(180) 
72.3 ± 2.0 
 
(80) 
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2 & 3 
P-value 
MEN 
N 128 4 12 67 83 21   
Age (y) 59.4 ± 1.4 
a 
77.2 ± 8.1 
b 
57.2 ± 4.7 
c 
65.4 ± 2.0 
d 
66.1 ± 1.8 
e 
56.3 ± 3.6 
f 
a vs b, d, & 
e <0.05 
b vs c & f 
<0.05 
d vs f 
<0.05 





176.9 ± 0.6  167.7 ±3.7  176.6 ± 2.2  175.3 ± 0.9  176.1 ± 0.8  177.0 ± 1.6 b vs a, c, d, 




85.4 ± 1.1 91.8 ± 6.4 80.4 ± 3.7 82.8 ± 1.6 83.1 ± 1.4 87.5 ± 2.8 0.271 
WOMEN 
N 108 10 17 53 65 25  
Age (y) 58.8 ± 1.6 59.7 ± 5.1 59.0 ± 4.0  55.7 ± 2.2 55.9 ± 2.0  55.1 ± 3.3  0.732 
Height 
(cm) 
163.2 ± 0.7 
 
(99) 
163.2 ± 2.2 
 
(10) 
161.2 ± 1.7 
 
(14) 
164.9 ± 0.9 
 
(49) 
163.1 ± 0.8 
 
(61) 






65.4 ± 1.2 
a 
67.3 ± 3.9 69.2 ± 3.0 71.3 ± 1.7 
b 
69.0 ± 1.5 64.1 ± 2.5 
c 
b vs a 
0.005 
b vs c  
0.018 
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Table N: Soft tissue FFM variables for Follistatin haplotype groups in Caucasian 






























57.4 ± 0.4 
a 
(128) 
65.1 ± 2.4 
b 
(4) 
57.4 ± 1.3 
c 
(12) 
56.9 ± 0.6 
d 
(67) 
56.1 ± 0.5 
e 
(83) 
56.9 ± 1.0 
f 
(21) 
b vs a, c, 





17.8 ± 0.3 
a 
(116) 
17.4 ± 1.4 
 
(4) 
17.4 ± 1.0 
 
(9) 
17.1 ± 0.4 
 
(62) 
16.7 ± 0.3 
b 
(72) 
15.8 ± 0.7 
c 
(17) 







39.0 ± 0.3 
a 
(108) 
39.2 ± 1.1 
 
(10) 
39.8 ± 0.8 
 
(17) 
40.3 ± 0.5 
b 
(53) 
39.9 ± 0.4 
 
(65) 
39.2 ± 0.7 
 
(25) 






11.0 ± 0.2 
 
(99) 
11.8 ± 0.7 
 
(10) 
11.8 ± 0.6 
 
(14) 
11.6 ± 0.3 
 
(49) 
11.8 ± 0.3 
 
(61) 




Data are least squares means ± SE.  Age and height were included in the model as 
significant covariates. 
 
Table O: Concentric knee extensor peak torque values for Follistatin haplotype 























































































































74.2 ± 1.8 
 
(94) 
72.8 ± 6.5 
 
(7) 
68.8 ± 4.7 
 
(14) 
72.2 ± 2.5 
 
(50) 
70.0 ± 2.4 
 
(55) 




Data are least square means ± SE.  Age and height were included in the model as 
significant covariates 
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